Female Reproductive & Breast

Uterine fibroids: management options

Clinical Overview and When to Suspect Uterine Fibroids

— Cumulative incidence by age 50: ~70% in white women, ~80% in Black women

— Black women: earlier onset, larger/more numerous fibroids, more severe symptoms, higher hysterectomy rates

— Peak symptomatic presentation: ages 30–50; regress after menopause

— Black race, early menarche, nulliparity, obesity, family history, hypertension

— Protective: parity, combined hormonal contraceptives, late menarche, smoking (not recommended)

— Heavy menstrual bleeding (HMB) with iron-deficiency anemia in a 35–50-year-old

— Bulk symptoms: pelvic pressure, urinary frequency, constipation, dyspareunia

— Enlarged, irregular, mobile, non-tender uterus on bimanual exam

— Infertility or recurrent pregnancy loss with submucosal pattern

— 0–2: submucosal (cause heaviest bleeding, fertility impact)

— 3–5: intramural

— 6–7: subserosal (cause bulk symptoms)

— 8: cervical, parasitic, broad ligament

— Symptom-directed management — asymptomatic fibroids found incidentally generally need no treatment, only reassurance and routine follow-up

— Treatment decisions depend on: symptom severity, fertility desire, fibroid size/location, patient age, proximity to menopause

— Rapid growth (especially postmenopausal)

— Postmenopausal bleeding

— Persistent pain unresponsive to therapy

Board pearl: Postmenopausal growth of a "fibroid" should raise concern for leiomyosarcoma — refer for surgical evaluation rather than morcellation-based procedures. Most fibroids, however, shrink after menopause; growth in that setting is the red flag.

Definition: Uterine leiomyomas are benign monoclonal smooth-muscle tumors of the myometrium, the most common pelvic tumor in reproductive-age women.

Epidemiology:

Risk factors:

When to suspect on Step 3:

Classification (FIGO 0–8):

Outpatient framing (Step 3 voice):

Red flags prompting deeper workup:

Presentation Patterns and Key History

— Abnormal uterine bleeding (AUB-L in PALM-COEIN): heavy, prolonged menses; intermenstrual spotting less typical

— Bulk symptoms: pelvic pressure/fullness, urinary frequency or retention (anterior fibroids compressing bladder), constipation/tenesmus (posterior), back pain, hydronephrosis if very large

— Reproductive dysfunction: infertility, recurrent miscarriage, malpresentation, preterm labor

— Quantify: pad/tampon changes per hour, clots >1 inch, flooding, double protection, missed work/school

— Duration >7 days, cycle length, intermenstrual bleeding

— Symptoms of anemia: fatigue, dyspnea on exertion, pica, restless legs

— Dysmenorrhea (often crampy, with bleeding)

— Acute severe pain → suspect degenerating fibroid (especially in pregnancy, red degeneration) or torsion of pedunculated subserosal fibroid

— Dyspareunia, particularly with posterior/fundal fibroids

— Gravidity/parity, prior pregnancy losses, current fertility goals

— Contraceptive use and tolerance

— Time to menopause (vasomotor symptoms, cycle changes)

— Prior anemia, transfusions, iron therapy

— Prior myomectomy or uterine surgery (recurrence risk ~50% over 5 years)

— Bleeding disorders (always screen — von Willebrand disease in adolescents/young women with HMB)

— Impact on work, quality of life (validated tool: UFS-QOL)

— Cultural views on hysterectomy, fertility preservation values

Step 3 management: In a woman with HMB, always screen for bleeding disorders (PT/PTT, vWF antigen/activity, ristocetin cofactor) when bleeding began at menarche, family history is positive, or there is a personal bleeding history — fibroids and bleeding disorders frequently coexist and the diagnosis changes management entirely.

Three classic symptom clusters — anchor your history around these:

Bleeding history specifics:

Pain patterns:

Reproductive history:

Past medical:

Medications: anticoagulants, hormonal therapy, NSAID use, supplements

Social/health-systems framing:

Physical Exam Findings and Hemodynamic Assessment

— Pallor, conjunctival pallor → anemia

— Tachycardia, orthostatic vitals → acute or chronic blood loss

— BMI documentation (affects surgical approach, anesthesia risk)

— Palpable suprapubic or lower abdominal mass arising from pelvis ("cannot get below it")

— Uterine size often described in weeks-gestation equivalents (e.g., "16-week-size uterus")

— Non-tender unless degenerating, torsed, or infected

— Speculum: assess for active bleeding, cervical lesions, prolapsing submucosal fibroid through os (pedunculated leiomyoma)

— Bimanual: enlarged, irregular, firm, mobile uterus with bosselated contour; non-tender

— Mobility distinguishes fibroid uterus (usually mobile) from adenomyosis (boggy, tender, less irregular) and pelvic adhesions/malignancy (fixed)

— Cervical motion tenderness should be absent — its presence suggests PID or other pathology

— Vitals q15min if actively bleeding heavily

— Tachycardia >100, SBP <90, orthostasis, capillary refill >3 sec → resuscitate

— Establish two large-bore IVs, type and screen, CBC, coags

— Costovertebral angle tenderness or flank fullness → hydronephrosis from ureteral compression

— Lower-extremity edema, varicosities → IVC/iliac vein compression (rare but tested)

— DVT risk from pelvic venous compression — examine calves

CCS pearl: For a woman presenting to the ED with acute severe HMB and a known fibroid uterus, your CCS order set should include: vitals, large-bore IV access, CBC, type and screen, coagulation panel, IV fluids, transfuse if Hb <7 or symptomatic, IV tranexamic acid, and high-dose oral or IV conjugated estrogens while obtaining urgent gynecology consult.

General appearance:

Abdominal exam:

Pelvic exam:

Rectovaginal exam: evaluates posterior fibroids, cul-de-sac nodularity (think endometriosis differential)

Hemodynamic assessment in acute HMB:

Signs of compression complications:

Diagnostic Workup — Initial Labs and Imaging

— CBC: microcytic anemia is the hallmark; check MCV, RDW

— Iron studies: ferritin (most sensitive), serum iron, TIBC, transferrin saturation — confirm iron deficiency before empiric iron

— Urine β-hCG: mandatory in any reproductive-age woman with AUB before treatment or imaging-guided procedures

— TSH: rule out thyroid-related AUB

— Prolactin: if galactorrhea or oligomenorrhea

— Coagulation panel + vWD workup when indicated (see Chunk 2)

— Type and screen if heavy active bleeding

— Transvaginal ultrasound (TVUS): initial study of choice

– Sensitivity ~90–99% for fibroids >5 mm

– Identifies number, size, location (intramural/subserosal); limited for small submucosal lesions

– Hypoechoic or heterogeneous well-circumscribed masses with posterior shadowing; calcifications common in older fibroids

— Saline infusion sonohysterography (SIS): when submucosal involvement suspected (HMB, infertility) — better characterizes cavity

— Hysteroscopy: both diagnostic and therapeutic for submucosal fibroids

— Indicated in AUB with: age ≥45, age <45 with risk factors for hyperplasia (obesity, PCOS, unopposed estrogen, Lynch syndrome, tamoxifen, persistent bleeding despite therapy)

— Rules out endometrial hyperplasia/carcinoma — a critical differential in AUB

Key distinction: TVUS identifies fibroids; SIS or hysteroscopy is needed to confirm submucosal location (FIGO 0–2), which determines whether hysteroscopic myomectomy is feasible. Don't commit to a procedural plan from TVUS alone if the cavity is the concern.

Initial laboratory evaluation:

Imaging — first-line:

Endometrial sampling (endometrial biopsy):

Pap and STI testing: age-appropriate cervical cancer screening; GC/chlamydia if risk factors

Pregnancy test: every time — repeat if symptoms evolve

Diagnostic Workup — Advanced and Confirmatory Studies

— Best for surgical planning: precise mapping of fibroid number, size, FIGO type, and relationship to endometrium, serosa, and adjacent organs

— Distinguishes fibroids from adenomyosis (junctional zone >12 mm, ill-defined borders) and from adnexal masses

— Required for uterine artery embolization (UAE) and MR-guided focused ultrasound (MRgFUS) planning

— Helps differentiate benign fibroid from leiomyosarcoma (atypical features: T2 heterogeneity, restricted diffusion, central necrosis) — though no imaging fully excludes sarcoma

— Direct visualization and simultaneous resection of FIGO 0–2 fibroids

— Best for submucosal disease causing HMB or infertility

— Diagnostic role limited; mainly therapeutic (myomectomy) or to evaluate concurrent endometriosis

— CA-125 may be mildly elevated in fibroids, adenomyosis, endometriosis — not diagnostic and not routinely ordered unless adnexal mass suspected

— LDH elevation with specific MRI features has been studied in sarcoma — not standard of care

— Anemia correction goal Hb >10–12 prior to elective surgery

— Type and crossmatch for myomectomy/hysterectomy

— Pregnancy test day-of-surgery

— Anesthesia evaluation, cardiopulmonary risk stratification per ACC/AHA perioperative guidelines

Board pearl: MRI is not first-line for diagnosis — TVUS is. MRI's role is surgical/procedural planning and complex cases (very large uteri, suspected adenomyosis, sarcoma concern, planning UAE or MRgFUS). Ordering MRI as the initial test is a wrong-answer trap on Step 3.

MRI pelvis (with and without contrast):

CT: not routine for fibroids; may incidentally identify them or detect hydronephrosis/complications

Hysteroscopy:

Laparoscopy:

Endometrial biopsy revisited: before any planned surgery for AUB to rule out occult malignancy, especially in women ≥45

Tumor markers — caution:

Pre-procedural workup for surgical candidates:

Fertility workup: if infertility is the indication — semen analysis, ovulation assessment, tubal patency (HSG) before attributing infertility to fibroids

Risk Stratification and First-Line Management Logic

— Symptoms? Asymptomatic → observation. Symptomatic → treat.

— Fertility desired? Yes → uterus-sparing. No/complete → hysterectomy is definitive.

— Dominant symptom? Bleeding vs. bulk vs. both.

— No treatment regardless of size in most cases

— Reassurance + annual exam; repeat imaging only if symptoms change

— Exceptions warranting intervention: hydronephrosis, inability to evaluate adnexa, suspicion of malignancy

— Medical therapy first → procedural if failed, contraindicated, or patient preference

— Stepwise: NSAIDs + tranexamic acid → hormonal (combined OCPs, progestin-only, LNG-IUD) → GnRH antagonist combo therapy → surgical

— Medical therapy less effective for bulk; procedural management is mainstay

— GnRH agonists/antagonists can shrink fibroids 30–50% but only short-term bridge to surgery

— Myomectomy (hysteroscopic, laparoscopic, abdominal) is gold standard

— UAE traditionally not recommended for women desiring future pregnancy (relative contraindication; impaired ovarian/uterine perfusion)

— MRgFUS: fertility data limited

— Time-limited approach: medical bridging until menopause when fibroids regress naturally

— Especially useful for women within 2–3 years of expected menopause

Step 3 management: A 42-year-old with HMB, mild bulk symptoms, completed childbearing, and Hb 9.5 — the correct stepwise outpatient plan is iron repletion + tranexamic acid during menses + LNG-IUD as first-line definitive medical therapy (52 mg levonorgestrel device), with reassessment at 3 and 6 months before escalating to procedural options.

Core decision tree — three branch points drive every management choice:

Asymptomatic fibroids:

Symptomatic — bleeding-dominant:

Symptomatic — bulk-dominant:

Fertility-preserving options:

Definitive therapy: hysterectomy — only cure, eliminates recurrence

Perimenopausal patients:

Pharmacotherapy — First-Line Medical Regimens

— NSAIDs (mefenamic acid, ibuprofen, naproxen): reduce blood loss 20–40%, also treat dysmenorrhea; start at menses onset

— Tranexamic acid (TXA): 1300 mg PO TID for up to 5 days per cycle; reduces bleeding 30–55%; contraindicated in active thromboembolism, history of VTE

— Iron supplementation: oral ferrous sulfate 325 mg every other day (better absorption than daily); IV iron if intolerant or severe anemia

— Levonorgestrel IUD (52 mg): most effective medical therapy for fibroid-related HMB; reduces blood loss 70–90%; works best when cavity is not distorted (caution with submucosal fibroids — higher expulsion rates)

— Combined hormonal contraceptives: modest bleeding reduction; useful for contraception + cycle control

— Progestin-only pills, DMPA, etonogestrel implant: reduce bleeding; cause irregular spotting

— Elagolix + estradiol/norethindrone add-back (Oriahnn): up to 24 months; reduces HMB ~70%

— Relugolix + estradiol/norethindrone (Myfembree): once daily; similar efficacy

— Add-back therapy mitigates hypoestrogenic symptoms and bone loss

— Monitor bone density if used >24 months

— Short-term (≤6 months) preoperative use to shrink fibroids and correct anemia

— Causes menopausal symptoms; bone loss limits duration

— Initial flare in first 1–2 weeks

Board pearl: The LNG-IUD is first-line medical therapy for fibroid-associated HMB in women without significant cavity distortion. It outperforms combined OCPs and is preferred when contraception is also desired. Always rule out endometrial pathology (biopsy if ≥45 or risk factors) before placement.

Non-hormonal options (bleeding-dominant, fertility-compatible):

Hormonal therapy:

GnRH antagonists (oral, current first-line "specialty" medical therapy):

GnRH agonists (leuprolide):

Selective progesterone receptor modulators (ulipristal acetate): restricted/withdrawn in US due to hepatotoxicity concerns — generally not on Step 3 answers

Contraindications across hormones: active VTE, estrogen-sensitive cancer, severe liver disease, undiagnosed AUB before workup

Procedural and Surgical Management

— Indication: FIGO type 0–2 submucosal fibroids <4–5 cm

— Outpatient, fertility-preserving, rapid recovery

— Risk: fluid overload/hyponatremia with hypotonic distending media — monitor deficit

— FIGO 2–6 fibroids, generally ≤4–5 fibroids, uterus <16 weeks

— Fertility-preserving; cesarean delivery often recommended for future pregnancies if myometrium fully entered (rupture risk)

— Avoid power morcellation without containment — FDA warning for occult sarcoma dissemination

— Multiple/large fibroids, distorted anatomy

— Higher blood loss, longer recovery; preserves fertility

— Interventional radiology, occlusion of bilateral uterine arteries with microspheres

— Excellent for bleeding and bulk; symptom improvement ~85%

— Avoid in women desiring future pregnancy (relative contraindication)

— Post-embolization syndrome: pain, fever, nausea for 24–72h

— Noninvasive thermal ablation; outpatient

— Limited to accessible, non-pedunculated fibroids; fewer than 6, uterus <24 weeks

— Definitive cure; only option that eliminates recurrence risk

— Routes: vaginal (preferred when feasible), laparoscopic, robotic, abdominal — chosen by uterine size, prior surgery, surgeon expertise

— Ovarian conservation preferred in premenopausal women without ovarian pathology

CCS pearl: Before any uterine-sparing fibroid procedure, document fertility plans, obtain endometrial sampling if AUB and age ≥45, correct anemia (Hb >10), and discuss recurrence risk (~15–30% need re-intervention within 5 years after myomectomy or UAE).

Hysteroscopic myomectomy:

Laparoscopic/robotic myomectomy:

Abdominal (open) myomectomy:

Uterine artery embolization (UAE):

MR-guided focused ultrasound (MRgFUS):

Radiofrequency volumetric thermal ablation (Acessa, Sonata): uterine-conserving, growing role

Endometrial ablation: treats bleeding but not bulk; only when cavity is suitable; contraindicated if future fertility desired

Hysterectomy:

Special Populations — Older Adults and Renal/Hepatic Impairment

— Fibroids typically regress after menopause due to estrogen withdrawal

— Growth or new symptoms after menopause are red flags for leiomyosarcoma — prompt MRI and surgical evaluation

— Postmenopausal bleeding mandates endometrial sampling regardless of known fibroids

— Avoid systemic estrogen therapy without progestin if uterus present; monitor symptomatic fibroid response if MHT initiated

— NSAIDs: avoid in CKD stages 3b–5; risk of AKI, hyperkalemia

— TXA: dose-adjust in renal impairment (CrCl <50: reduce dose; CrCl <10: contraindicated by some sources)

— Iron sucrose/ferric carboxymaltose: preferred in CKD with iron deficiency anemia

— Contrast for MRI/UAE: assess eGFR; gadolinium contraindicated if eGFR <30 (NSF risk with older agents)

— Hydronephrosis from large fibroids can itself cause obstructive nephropathy — surgical decompression indicated

— Ulipristal — hepatotoxicity led to market restrictions; avoid

— Elagolix/relugolix: contraindicated in severe hepatic impairment (Child-Pugh C); caution in moderate

— Estrogen-containing therapy: avoid in active liver disease, hepatic adenoma, severe cirrhosis

— TXA: generally safe, no specific hepatic dose adjustment

— Fibroid HMB markedly worsened on anticoagulants

— Consider LNG-IUD, TXA (with caution if on DOACs), bridging strategies

— Multidisciplinary input with hematology

— Severe anemia can precipitate angina, heart failure — aggressive iron repletion and bleeding control

— Hormonal therapy with estrogen contraindicated in CAD, prior stroke, uncontrolled HTN, smokers >35

Board pearl: A postmenopausal woman with a rapidly enlarging "fibroid," weight loss, or new pelvic pain needs MRI and gynecologic oncology referral for leiomyosarcoma evaluation — do not perform morcellation-based procedures in this setting.

Perimenopausal and postmenopausal patients:

Renal impairment considerations:

Hepatic impairment:

Anticoagulated patients:

Cardiovascular comorbidity:

Special Populations — Pregnancy and Reproductive Subgroups

— Found in ~10% of pregnancies; most asymptomatic

— May grow in first/second trimester due to estrogen, then plateau or shrink

— Red degeneration: painful infarction of fibroid in pregnancy — severe localized pain, low-grade fever, leukocytosis, nausea

– Management: supportive — rest, hydration, acetaminophen, short-course NSAIDs (avoid after 32 weeks due to ductus arteriosus closure), opioids if needed; resolves in days to weeks

— Increased risk: miscarriage, preterm labor, placental abruption (especially retroplacental fibroids), malpresentation, fetal growth restriction, cesarean delivery, postpartum hemorrhage

— Submucosal and large (>5 cm) fibroids carry highest risk

— Fibroids alone are not an indication for cesarean unless obstructing the lower uterine segment or malpresentation

— Prior myomectomy entering the cavity → scheduled cesarean at 37–38 weeks; avoid labor due to rupture risk (similar counseling to classical cesarean)

— Prior UAE → counsel on increased obstetric risks; cesarean often recommended

— Higher PPH risk — anticipate with active management of third stage, uterotonics ready, large-bore IV, type and screen

— Fibroids generally regress postpartum

— Fibroids uncommon; if present with HMB, always screen for inherited bleeding disorders (vWD)

— Consider hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome if early-onset, multiple fibroids, family history of skin leiomyomas or RCC — fumarate hydratase mutation

— Submucosal (FIGO 0–2) fibroids reduce implantation/live birth; myomectomy improves outcomes

— Intramural fibroids distorting cavity: consider removal

— Subserosal fibroids: generally do not affect fertility

Step 3 management: Acute painful fibroid in a 24-week pregnant patient → diagnose red degeneration clinically + bedside US, manage with hydration, acetaminophen, and short-course opioids; avoid NSAIDs in third trimester; reassure that this is self-limited and not an indication for surgery.

Fibroids in pregnancy:

Obstetric complications associated with fibroids:

Mode of delivery:

Postpartum considerations:

Adolescents and young women:

Infertility evaluation:

Complications and Adverse Outcomes

— Iron deficiency anemia — most common complication; may progress to symptomatic anemia requiring transfusion

— Rarely, polycythemia from fibroid erythropoietin secretion (paraneoplastic, board trivia)

— Hydronephrosis from ureteral compression — may cause obstructive nephropathy

— Urinary frequency, urgency, retention (rare, acute urinary retention can occur with incarcerated fibroid)

— Recurrent UTIs

— Constipation, tenesmus from posterior fibroids

— Rarely, bowel obstruction

— DVT/PE from pelvic venous compression — fibroid uterus is an underrecognized VTE risk factor

— IVC compression in massive fibroids

— Torsion of pedunculated subserosal fibroid: acute severe pain, peritoneal signs; surgical emergency

— Degeneration (red, hyaline, cystic, calcific): pain, low-grade fever; usually managed conservatively

— Prolapsing submucosal fibroid: vaginal mass, bleeding, infection; transvaginal myomectomy

— Leiomyosarcoma — rare (~1 in 1,000–2,000 of presumed fibroids); cannot be reliably distinguished preoperatively; risk factor for inadvertent dissemination with power morcellation (FDA black box)

— Infertility, recurrent pregnancy loss, obstetric complications (Chunk 10)

— Hysteroscopy: fluid overload, hyponatremia, perforation

— UAE: post-embolization syndrome, ovarian failure (~5%, higher in older women), non-target embolization, infection

— Myomectomy: blood loss, transfusion, adhesions, uterine rupture in subsequent pregnancy

— Hysterectomy: ureteral injury, bladder injury, vaginal cuff dehiscence, VTE, ovarian failure if oophorectomy

Key distinction: Degeneration (subacute pain, low-grade fever, conservative management) versus torsion (sudden severe pain, peritoneal signs, surgical emergency) versus leiomyosarcoma (postmenopausal growth, weight loss, imaging features) — three "fibroid pain" presentations with very different responses.

Hematologic:

Genitourinary:

Gastrointestinal:

Vascular:

Acute fibroid events:

Malignancy:

Reproductive:

Procedural complications:

When to Escalate — ED, ICU, Consult, and Inpatient Triage

— Hemodynamic instability from acute HMB: tachycardia, hypotension, orthostasis

— Hemoglobin <7 g/dL or symptomatic anemia (chest pain, dyspnea, syncope)

— Acute urinary retention or obstructive uropathy with AKI

— Acute severe pelvic pain with peritoneal signs (suspected torsion/degeneration with peritonitis)

— Suspected fibroid degeneration with high fever (rule out infection/pyomyoma)

— Postoperative complications: bleeding, infection, ileus, VTE

— Active heavy bleeding requiring transfusion or IV hormonal therapy

— Prolapsing fibroid through cervix

— Pregnancy with severe fibroid complications

— Suspected leiomyosarcoma (rapid growth, postmenopausal, imaging concern)

— Two large-bore IVs, IV fluids, type and crossmatch

— Transfuse PRBCs if Hb <7 or symptomatic

— IV conjugated estrogens 25 mg q4–6h (up to 6 doses) — first-line pharmacologic for acute bleeding

— Or high-dose oral combined OCP (e.g., one tab TID × 7 days)

— IV/PO tranexamic acid as adjunct

— Antiemetics with high-dose estrogen

— If refractory → emergent uterine artery embolization or hysterectomy

— Massive transfusion protocol activation

— DIC from severe hemorrhage

— Postoperative respiratory failure, septic shock from pyomyoma

— Acute bleeding refractory to medical therapy in poor surgical candidates

— Definitive UAE planning

— Suspected or known bleeding disorder

— Anticoagulated patients with severe HMB

— Massive transfusion management

CCS pearl: For acute severe fibroid hemorrhage, your initial CCS orders should pair resuscitation + IV conjugated estrogens + tranexamic acid + GYN consult simultaneously — don't sequence them. Reassess vitals and Hb every 4–6 hours; advance the clock cautiously.

Emergency department / inpatient admission criteria:

Urgent gynecology consultation:

Acute medical management of severe HMB (CCS framework):

ICU criteria:

Interventional radiology consult:

Hematology consult:

Key Differentials — Other Gynecologic Causes of AUB and Pelvic Mass

— Polyps: focal endometrial overgrowth; intermenstrual bleeding; diagnose on SIS/hysteroscopy

— Adenomyosis: ectopic endometrial glands in myometrium; dysmenorrhea + HMB + diffusely enlarged, tender, boggy uterus; MRI shows junctional zone >12 mm

— Leiomyoma: the topic

— Malignancy/hyperplasia: endometrial carcinoma — must rule out in women ≥45 or with risk factors

— Coagulopathy: vWD, thrombocytopenia, anticoagulants

— Ovulatory dysfunction: PCOS, thyroid disease, perimenopause

— Endometrial causes: chronic endometritis

— Iatrogenic: hormonal contraception, anticoagulants, IUDs

— Not yet classified

— Both cause intermenstrual bleeding; SIS/hysteroscopy distinguishes

— Polyps are endometrial; fibroids are myometrial extending into cavity

— Adenomyosis: diffusely enlarged, globular, tender, boggy uterus; cycle-related pain prominent

— Fibroids: irregular, bosselated, mobile, usually non-tender

— Often coexist; MRI clarifies

— Postmenopausal bleeding or AUB with risk factors (obesity, unopposed estrogen, PCOS, tamoxifen, Lynch)

— Always biopsy before attributing AUB to fibroids in at-risk patients

— Pedunculated subserosal fibroid can mimic adnexal mass; MRI clarifies

— Ovarian cancer: ascites, weight loss, elevated CA-125 with concerning features

Key distinction: Adenomyosis = tender, boggy, symmetrically enlarged uterus + dysmenorrhea + HMB, while fibroid uterus = non-tender, irregular, asymmetrically enlarged. They commonly coexist, and management differs (LNG-IUD excellent for both; hysterectomy is curative for adenomyosis, myomectomy is not).

PALM-COEIN framework (structural vs nonstructural causes of AUB):

Endometrial polyps vs submucosal fibroids:

Adenomyosis vs fibroids:

Endometrial hyperplasia/carcinoma:

Ovarian/adnexal masses:

Cervical pathology: cervical cancer, polyps — speculum exam and Pap

Pregnancy-related bleeding: ectopic, miscarriage, GTD — always check β-hCG

Key Differentials — Non-Gynecologic and Systemic Causes

— Colorectal malignancy presenting with pelvic mass, constipation, weight loss — colonoscopy in age-appropriate patients

— Diverticular abscess, inflammatory bowel mass

— Appendiceal mass (mucocele, neoplasm)

— Distended bladder (urinary retention) palpable suprapubically — bladder scan/catheterize before assuming pelvic mass

— Bladder tumors, pelvic kidney

— Sarcomas, lymphadenopathy, lymphoma

— Pelvic kidney, horseshoe kidney

— Always rule out with β-hCG before any pelvic mass workup or fibroid intervention

— Molar pregnancy, ectopic, normal intrauterine pregnancy with coincident fibroid

— Thyroid disease: both hypo- and hyperthyroidism alter menstrual patterns

— Hyperprolactinemia: oligomenorrhea, galactorrhea

— PCOS: oligo-ovulation, hyperandrogenism, anovulatory AUB with characteristic ovarian morphology

— Adrenal disorders: rare

— von Willebrand disease (most common inherited bleeding disorder; 1% population) — screen with vWF antigen, ristocetin cofactor, factor VIII

— Platelet function disorders, ITP, thrombocytopenia

— Anticoagulant therapy

— Acquired coagulopathy from liver disease, vitamin K deficiency

— Pelvic inflammatory disease / tubo-ovarian abscess: fever, CMT, cervical discharge — distinct from fibroid presentation

— Pyomyoma: infected degenerating fibroid, rare but life-threatening

— GI bleeding (occult), malabsorption (celiac), chronic disease, hemoglobinopathy

— Always confirm iron deficiency biochemically and consider age-appropriate GI workup

Board pearl: In a 50-year-old woman with new-onset HMB and a "fibroid uterus," do not skip endometrial biopsy and age-appropriate colon cancer screening — both endometrial and colon cancer are competing diagnoses, and missing them is the classic Step 3 trap.

Gastrointestinal mimics:

Urologic mimics:

Retroperitoneal masses:

Pregnancy:

Endocrine causes of AUB:

Hematologic disorders:

Infectious:

Systemic disease causing fatigue/anemia mimicking fibroid anemia:

Secondary Prevention, Long-Term Plan, and Discharge Medications

— Continue iron supplementation until ferritin normalizes (>50 ng/mL), then reassess

— Reassess bleeding pattern at 3 and 6 months

— IUD effective for 8 years for HMB indication (extended duration data)

— Expect irregular spotting first 3–6 months; counsel on expulsion risk (~10% with cavity distortion)

— Counsel 5-year recurrence rate 15–30%; risk higher with multiple fibroids

— Contraception for at least 3 months (or longer if cavity entered) before attempting pregnancy

— Future pregnancy: planned cesarean if myometrium fully transected

— Continue iron until ferritin replete

— Consider postoperative LNG-IUD or OCPs to suppress recurrence symptoms if no fertility plans

— Expect symptom improvement over 3–6 months

— Reimaging at 6 months

— Discuss ovarian failure risk (~5%, higher >45 years)

— Pregnancy not recommended; if desired, counsel risks

— Definitive — no fibroid recurrence

— If ovaries retained: continue routine screening, monitor for menopause

— If oophorectomy in premenopausal: discuss hormone therapy unless contraindicated to reduce CV, bone, cognitive risks (especially if <45)

— Pelvic floor PT if symptoms; sexual health counseling

— Maintain healthy BMI (obesity ↑ fibroid risk and recurrence)

— Treat hypertension

— Vitamin D repletion (associated with lower fibroid risk in observational data)

— Continue age-appropriate cancer screening (cervical, breast, colorectal)

— Recheck CBC at 4–8 weeks after intervention

— Continue oral iron 3–6 months after Hb normalization to replete stores

Step 3 management: After hysterectomy with bilateral oophorectomy in a 41-year-old for fibroids, initiate systemic estrogen therapy (no progestin needed without uterus) at least until average age of menopause (~51) to mitigate cardiovascular, osteoporotic, and cognitive risks — this is a frequently missed Step 3 point.

Post-medical therapy plan (e.g., started on LNG-IUD):

Post-myomectomy:

Post-UAE:

Post-hysterectomy:

General secondary prevention:

Anemia follow-up:

Follow-Up, Monitoring Parameters, and Counseling

— Annual gynecologic exam

— Repeat imaging only if symptoms develop or exam changes

— No routine surveillance imaging needed

— LNG-IUD: check strings annually; symptom reassessment 3 and 6 months; expulsion risk highest first 3 months

— GnRH antagonist + add-back: bone density (DEXA) baseline and at 1 year if continued; lipid panel; monitor LFTs (relugolix)

— GnRH agonist (leuprolide): limit to 6 months without add-back; monitor menopausal symptoms; DEXA if extended

— Combined hormonal contraceptives: BP monitoring, VTE risk reassessment, age <35 smoking screen

— Iron therapy: recheck CBC and ferritin 4–8 weeks after initiation; continue until ferritin >50 ng/mL

— Postoperative visit at 2 and 6 weeks

— UAE: clinical reassessment 1, 3, 6 months; imaging at 6 months

— Myomectomy: pelvic ultrasound at 6 months and annually for recurrence in symptomatic patients

— Validated tools: UFS-QOL (Uterine Fibroid Symptom and Health-Related Quality of Life)

— Document menstrual diary, pain scores, functional status

— Recurrence risk after uterus-sparing procedures

— Future pregnancy considerations and timing

— Realistic expectations: medical therapy controls symptoms; only hysterectomy is curative

— Sexual function: most procedures do not impair sexual function; hysterectomy generally improves QoL in symptomatic patients

— Bone health for those on prolonged hypoestrogenic therapy: calcium 1000–1200 mg/day, vitamin D 800–1000 IU/day, weight-bearing exercise

— Weight management, exercise, vitamin D repletion, smoking cessation

Board pearl: When initiating a GnRH antagonist combination therapy for fibroids, document baseline DEXA if planned use >1 year and counsel on contraception (these regimens are not reliable contraceptives despite suppressing ovulation in many — use barrier or non-hormonal methods unless specified).

Asymptomatic fibroids:

Patients on medical therapy:

Post-procedural follow-up:

Quality-of-life monitoring:

Counseling content:

Lifestyle counseling:

Ethical, Legal, and Patient Safety Considerations

— Permanent loss of fertility — particularly sensitive in younger women; document thorough discussion of alternatives

— Discuss ovarian conservation explicitly; default to conservation in premenopausal women without ovarian pathology (improves all-cause mortality)

— Cultural and religious considerations; involve patient's support system if desired

— Decision aids improve shared decision-making and are recommended

— FDA safety communications (2014, updated): power morcellation without containment contraindicated in most women undergoing fibroid surgery due to risk of disseminating occult sarcoma

— Document discussion; use contained morcellation systems when morcellation needed

— Higher risk in postmenopausal and older patients — avoid morcellation entirely in this group

— Black women experience earlier, more severe disease and disproportionately undergo hysterectomy rather than uterus-sparing procedures

— Step 3-level awareness: actively offer full range of options regardless of race; document shared decision-making

— Discharge after myomectomy/hysterectomy: clear instructions on VTE prophylaxis, activity restrictions, signs of complications, follow-up scheduling

— Medication reconciliation: stop estrogen-containing therapy before major surgery (4 weeks pre-op when feasible) to reduce VTE risk; restart appropriately

— Communicate with PCP regarding anemia follow-up, contraception plan, hormone therapy decisions

— Respect patient's fertility goals even when clinically "easier" options exist

— Do not coerce sterilization; offer myomectomy or medical management when feasible

— In adolescents with HMB, balance parental involvement with patient confidentiality per state law; address bleeding disorder workup sensitively

— Closed-loop communication, massive transfusion protocol readiness, time-out before procedures

Step 3 management: Before scheduling hysterectomy in a 35-year-old Black woman with symptomatic fibroids, explicitly document discussion of uterus-sparing alternatives (myomectomy, UAE, LNG-IUD, GnRH antagonist), her fertility goals, and the rationale for the chosen approach — this is both an equity issue and a documentation safeguard.

Informed consent for hysterectomy:

Power morcellation and occult leiomyosarcoma:

Racial disparities and equitable care:

Transition-of-care safety:

Reproductive autonomy:

Confidentiality and adolescents:

Patient safety in acute hemorrhage:

High-Yield Associations and Rapid-Fire Facts

Board pearl: If the question gives you HMB + microcytic anemia + irregular, non-tender, mobile, enlarged uterus + reproductive-age woman → answer transvaginal ultrasound as the next step, not MRI, not biopsy first unless ≥45 or risk factors.

Most common pelvic tumor in reproductive-age women

Black race: earlier onset, larger fibroids, more severe symptoms

PALM-COEIN: L = Leiomyoma, structural cause of AUB

FIGO classification 0–8: 0–2 submucosal, 3–5 intramural, 6–7 subserosal, 8 other

First-line imaging: transvaginal ultrasound

Best for cavity assessment: saline infusion sonohysterography or hysteroscopy

Best for surgical/procedural planning: MRI pelvis

Most effective medical therapy for HMB: LNG-IUD (52 mg)

Acute severe bleeding pharmacotherapy: IV conjugated estrogens + TXA

GnRH antagonist + add-back: elagolix or relugolix combos, oral, ≤24 months

Definitive cure: hysterectomy

Best for submucosal HMB or infertility: hysteroscopic myomectomy

Avoid UAE if: future pregnancy desired

Avoid power morcellation without containment: FDA black box (sarcoma risk)

Red degeneration: pregnancy + acute painful fibroid → supportive care

Postmenopausal growth: rule out leiomyosarcoma

Pedunculated subserosal fibroid + acute pain: torsion, surgical emergency

Prolapsing submucosal fibroid: vaginal mass via cervix, transvaginal myomectomy

Polycythemia from fibroid: rare paraneoplastic erythropoietin secretion

HLRCC syndrome: early multiple fibroids + skin leiomyomas + RCC (fumarate hydratase mutation)

Always rule out: pregnancy (β-hCG) and endometrial cancer (biopsy if ≥45 or risk factors)

vWD screen in young women with HMB since menarche

Iron repletion: oral every other day better than daily; IV iron if intolerant or severe

Post-myomectomy pregnancy: cesarean delivery if cavity entered

Recurrence after myomectomy/UAE: 15–30% over 5 years

Fibroids regress after menopause (estrogen-dependent)

Adenomyosis: tender, boggy, symmetric uterus (the mimic to remember)

DVT risk: large fibroids compress pelvic veins

Hydronephrosis: from ureteral compression — surgical indication

Board Question Stem Patterns

— 42-year-old Black woman with 6 months of HMB, fatigue, lower abdominal fullness; bimanual reveals 14-week-size irregular non-tender uterus; Hb 9.2

— Next step: TVUS; best initial medical therapy: LNG-IUD; concurrent: iron + TXA during menses

— Patient with known fibroids presents with flooding, dizziness, tachycardia, Hb 6.8

— Answer: resuscitate, transfuse, IV conjugated estrogens, TXA, GYN consult, consider UAE if refractory

— 33-year-old with 2 years infertility, normal partner workup, HMB; TVUS shows 3 cm submucosal fibroid

— Answer: hysteroscopic myomectomy

— 22 weeks pregnant, acute right-sided pain, known fibroid, low-grade fever, normal cervix, reassuring fetal status

— Answer: red degeneration; acetaminophen, hydration, supportive care

— 58-year-old, prior known fibroids, new pelvic pain and growing uterus, weight loss

— Answer: MRI + GYN oncology referral for leiomyosarcoma evaluation; avoid morcellation

— Tender, symmetrically enlarged, boggy uterus with HMB and severe dysmenorrhea

— Answer: adenomyosis, not fibroid; LNG-IUD or hysterectomy

— 17-year-old with HMB since menarche, easy bruising, family history of bleeding

— Answer: vWD workup before attributing to fibroids

— Wants future fertility → myomectomy; not UAE

— Completed childbearing, definitive cure desired → hysterectomy

— Hb 8.5 before elective myomectomy

— Answer: delay surgery, GnRH agonist 2–3 months + IV iron to optimize Hb >10–12

— 47-year-old, obese, AUB, fibroids on TVUS

— Answer: endometrial biopsy before treatment

Step 3 management: Recognize that Step 3 tests sequencing — they want the next best step in an ambulatory workflow: pregnancy test → CBC/iron → TVUS → endometrial biopsy if indicated → medical therapy → procedural therapy. Skipping steps is the wrong answer.

Pattern 1 — Classic presentation:

Pattern 2 — Acute hemorrhage:

Pattern 3 — Submucosal/infertility:

Pattern 4 — Pregnancy with painful fibroid:

Pattern 5 — Postmenopausal growth:

Pattern 6 — Adenomyosis distractor:

Pattern 7 — Bleeding disorder screen:

Pattern 8 — Choosing procedure by fertility:

Pattern 9 — Perioperative anemia optimization:

Pattern 10 — Endometrial sampling indication:

One-Line Recap

Uterine fibroids are benign, estrogen-driven myometrial tumors whose management is dictated by symptom pattern, fertility goals, and fibroid location — treat asymptomatic disease with reassurance, bleeding-dominant disease first with LNG-IUD and adjuncts, bulk-dominant disease with procedural therapy, and offer hysterectomy as the only definitive cure.

— Reproductive-age woman with HMB + irregular, non-tender, enlarged uterus → β-hCG, CBC/ferritin, TSH, TVUS first; endometrial biopsy if ≥45 or risk factors; SIS/hysteroscopy for cavity assessment; MRI for surgical planning

— Non-hormonal: NSAIDs + TXA + iron

— Hormonal first-line: LNG-IUD (most effective for HMB); alternatives include combined OCPs, progestins, GnRH antagonist + add-back (elagolix, relugolix), GnRH agonist (short-term preoperative)

— Hysteroscopic myomectomy for submucosal/cavity-involving fibroids

— Laparoscopic/abdominal myomectomy for fertility preservation

— UAE for bleeding/bulk in women not planning pregnancy

— MRgFUS/RF ablation for selected candidates

— Hysterectomy = definitive cure

— Always rule out pregnancy and endometrial cancer before attributing AUB to fibroids

— Postmenopausal growth → rule out leiomyosarcoma

— Avoid uncontained power morcellation

— Counsel future pregnancy mode of delivery after myomectomy entering cavity

— Address racial disparities by offering the full spectrum of uterus-sparing options

— In premenopausal hysterectomy with oophorectomy, start estrogen therapy until average age of menopause unless contraindicated

Board pearl: The single most testable Step 3 sequence is — confirm diagnosis with TVUS, rule out competing diagnoses (pregnancy, endometrial cancer, bleeding disorders), then match therapy to the patient's symptom pattern and fertility plan; never jump to surgery without exhausting appropriate medical therapy in stable outpatients, and never delay resuscitation in acute hemorrhage.

High-yield workflow recap:

Medical therapy recap:

Procedural recap:

Safety recap: